Egrifta (Tesamorelin) Pediatric (Under 12) Caregiver Administration Guidance

What Is Tesamorelin and Why Would a Child Under 12 Receive It?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile secretion of growth hormone, which in turn raises IGF-1 levels. The FDA approved tesamorelin (Egrifta SV, 2 mg) specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy. [1]

Children under 12 may occasionally be prescribed tesamorelin off-label by pediatric endocrinologists in highly specific clinical circumstances, such as growth hormone deficiency refractory to standard therapy, or as part of a supervised research protocol. Because this population is outside the labeled indication, no pediatric pharmacokinetic data from the key LIPO-010 and LIPO-011 trials apply directly. Caregivers must understand that the decision to prescribe reflects individualized clinical judgment, not a general standard of care.

Why the Off-Label Designation Matters for Caregivers

The FDA's approval of tesamorelin covers only adults. Any prescription for a child under 12 is issued under a physician's professional discretion. This means insurance coverage may be limited, and the prescribing team carries heightened responsibility for monitoring. Caregivers should confirm in writing that the prescribing physician has explained the rationale, expected benefits, and known risks before beginning therapy. [2]

How Tesamorelin Differs From Recombinant Human Growth Hormone

Tesamorelin does not supply exogenous growth hormone. It stimulates the child's own pituitary to produce it. This mechanism preserves the pulsatile, feedback-regulated pattern of GH secretion and may reduce the risk of GH excess compared with direct rhGH administration. In the key adult trials, tesamorelin raised IGF-1 by a mean of 97 ng/mL above placebo at 26 weeks (P<0.001). [3] Whether that magnitude of IGF-1 elevation applies to prepubertal children is not established.

Preparing the Injection: Step-by-Step Reconstitution

Reconstituting Egrifta SV correctly is the single most error-prone part of home administration. Errors at this stage can degrade the peptide, introduce particulates, or alter the delivered dose. Take each step slowly.

Supplies You Will Need

Gather the following before starting:

• One Egrifta SV 2 mg vial (lyophilized powder)
• One vial of sterile water for injection (2.1 mL, supplied by the manufacturer)
• Two alcohol swabs
• One 1 mL or 3 mL syringe with a reconstitution needle (18 to 21 gauge)
• One thin-wall 27 to 30 gauge, 4 to 8 mm subcutaneous injection needle
• A clean, flat surface (a paper towel on a countertop is adequate)
• A sharps disposal container

Always wash hands with soap and water for at least 20 seconds before touching any supply. [4]

Reconstitution Procedure

1. Remove both vials from the refrigerator 10 to 15 minutes before use. Cold protein solutions are more viscous and harder to draw up accurately.
2. Wipe both vial tops with separate alcohol swabs. Allow to air-dry for 10 seconds each. Do not blow on them.
3. Draw 2.1 mL of sterile water into the reconstitution syringe.
4. Inject the water slowly down the inside wall of the tesamorelin vial. Direct the stream against the glass, not onto the powder directly. This reduces foaming.
5. Gently roll the vial between your palms for 30 seconds. Do not shake. Shaking denatures the peptide and creates bubbles that make accurate dosing harder.
6. Inspect the solution. It must be clear and colorless, free of visible particles. If it appears cloudy or contains floating material, discard it and contact the pharmacy.
7. Draw up the prescribed dose immediately.

The reconstituted solution must be used within 3 hours if kept at 2 to 8°C. Discard any unused portion. [1]

Dose Adjustment in Children Under 12

The adult approved dose is 2 mg once daily. For a child under 12, the prescribing physician will specify a weight-based or age-adjusted dose. Follow that written instruction exactly. Do not round up or substitute a full adult vial dose without explicit physician approval.

Injection Technique for Subcutaneous Administration

Subcutaneous injection delivers the drug into the fatty tissue just beneath the skin. In young children, this layer is thinner than in adults, which changes needle length selection and pinching technique.

Choosing and Rotating Injection Sites

Approved subcutaneous sites for tesamorelin in adults are the abdomen, thighs, and upper arms. In young children, the abdomen is generally preferred because it offers a consistent fatty layer and is easiest for a caregiver to access. The prescribing nurse or physician will confirm which sites are appropriate for the individual child based on body composition.

Rotate sites systematically. A practical rotation map for young children:

• Week 1: Right abdomen, 2 cm outside the navel, upper quadrant
• Week 2: Left abdomen, 2 cm outside the navel, upper quadrant
• Week 3: Right abdomen, lower quadrant
• Week 4: Left abdomen, lower quadrant

Returning to the same spot within a 4-week cycle risks lipohypertrophy, which impairs absorption. A published meta-analysis of insulin injection studies (N=2,405 pooled) found lipohypertrophy at injection sites was associated with a 26% increase in glycemic variability; while those data involve insulin, the tissue-damage mechanism is the same for any peptide injected repeatedly into the same spot. [5]

Injection Steps

1. Pinch 1 to 2 inches of skin and fat between your thumb and forefinger. In lean children under 12, a 4 mm needle inserted at 45 degrees reduces intramuscular injection risk.
2. Insert the needle smoothly in one motion. Do not hesitate.
3. Release the pinch before depressing the plunger. Injecting while the tissue is pinched can cause bruising.
4. Depress the plunger slowly and steadily over 5 to 7 seconds.
5. Withdraw the needle at the same angle it was inserted.
6. Apply gentle pressure with a clean cotton ball. Do not rub; rubbing disperses the drug unevenly.
7. Immediately place the used needle in the sharps container without recapping.

Managing Injection-Site Reactions

Redness, mild swelling, and brief stinging are common after tesamorelin injections and typically resolve within 30 to 60 minutes. In the key adult LIPO-010 trial (N=273), injection-site erythema occurred in 8.7% of tesamorelin-treated subjects versus 3.5% of placebo subjects. [3] If a child develops a welt larger than 2 cm, skin hardening, or a reaction that persists more than 24 hours, document the site and contact the prescribing team before the next dose.

Storage and Handling

Proper storage protects peptide integrity and ensures the child receives an active dose at every injection.

Before Reconstitution

• Store Egrifta SV vials in the original carton in the refrigerator at 2 to 8°C (36 to 46°F).
• Never freeze. Freezing destroys the lyophilized matrix and may denature the peptide.
• Keep away from direct light.
• If the vial has been left at room temperature for more than 3 hours, discard it.

After Reconstitution

• Use within 3 hours of mixing.
• Keep the reconstituted syringe capped and in the refrigerator if there is any delay between reconstitution and injection.
• Never store a reconstituted, drawn syringe overnight. Prepared syringes are not stable for extended periods.

The FDA-approved prescribing information for Egrifta SV specifies these storage parameters explicitly. [1]

Traveling With Tesamorelin

Carry vials in an insulated cooler pack with an ice substitute. Airport security in the United States allows medically necessary injectable medications with appropriate documentation. Carry a letter from the prescribing physician on clinic letterhead that identifies the drug, the patient, and the diagnosis. TSA guidelines confirm that insulin and other liquid medications exceeding 3.4 oz (100 mL) are permitted when declared at security. [6]

Monitoring Parameters for Children Under 12

Because pediatric data for tesamorelin are limited, the prescribing physician will set a monitoring schedule. Caregivers should understand what is being measured and why.

IGF-1 Levels

Tesamorelin raises IGF-1. In growing children, IGF-1 drives longitudinal bone growth. Elevated IGF-1 above the age-adjusted normal range could accelerate bone age, potentially compromising final adult height. The Endocrine Society's clinical practice guideline on growth hormone deficiency states that IGF-1 should be monitored every 3 to 6 months during GH-stimulating therapy and kept within the age- and sex-specific normal range. [7]

Glucose Metabolism

Growth hormone reduces insulin sensitivity. In adult trials, tesamorelin did not significantly worsen fasting glucose versus placebo at 26 weeks, but the FDA label carries a warning for patients with pre-existing glucose intolerance. [1] In children with risk factors (obesity, family history of type 2 diabetes), fasting glucose and HbA1c should be checked at baseline and every 6 months.

Growth Velocity and Bone Age

A child's height and weight should be measured at every clinic visit and plotted on a standardized growth chart. Bone age radiographs (left-hand X-ray) may be ordered every 6 to 12 months to confirm that skeletal maturation is tracking appropriately for chronological age. Accelerated bone age that outpaces height gain can reduce final adult stature.

Fluid Retention

Tesamorelin can cause edema, arthralgia, and carpal tunnel syndrome through GH-mediated fluid retention. In the LIPO-010 trial, peripheral edema occurred in 6.1% of treated adults versus 2.2% of placebo. [3] In a child, the caregiver should watch for puffiness around the ankles and feet, tightness of shoes, or complaints of hand tingling. Report these promptly.

Side Effects: What Caregivers Must Recognize

Not all side effects require immediate action. Knowing which do helps caregivers respond proportionately.

Common Side Effects (Monitor, Do Not Panic)

• Injection-site redness or mild swelling (resolves within 1 hour)
• Brief muscle aching after the first few doses
• Mild, transient headache

These are consistent with GH-pathway activation and do not usually require dose interruption.

Side Effects Requiring Same-Day Contact With the Prescriber

• Persistent edema of the hands, feet, or face lasting more than 24 hours
• Fasting blood glucose above 126 mg/dL on a home glucometer reading
• Joint pain that limits range of motion
• Skin rash or hives beyond the injection site

Side Effects Requiring Emergency Care

• Signs of anaphylaxis: throat tightening, difficulty breathing, facial swelling, rapid pulse. Call 911. The incidence of systemic allergic reactions to tesamorelin in clinical trials was below 1%, but the reaction can be severe when it occurs. [1]
• Seizure or sudden loss of consciousness (may indicate severe hypoglycemia in the context of altered GH-insulin dynamics).

The American Academy of Pediatrics recommends that any caregiver administering injectable drugs to a child at home receive training in anaphylaxis recognition and epinephrine auto-injector use before the first home dose. [8]

Caregiver Training Requirements Before Home Administration

No caregiver should attempt home injection of tesamorelin in a child under 12 without completing a structured training program. This is not optional.

Minimum Training Checklist

A trained nurse or pharmacist should observe and sign off on each of the following before clearing the caregiver for independent home administration:

1. Correct hand-washing technique (minimum 20 seconds)
2. Vial inspection (checking expiration date, absence of particulates)
3. Sterile reconstitution from water vial to drug vial
4. Accurate dose measurement in the syringe
5. Air-bubble removal
6. Site selection and rotation documentation
7. Skin pinch and needle insertion technique on a training pad
8. Plunger depression speed and needle withdrawal
9. Sharps disposal
10. Recognition of anaphylaxis and use of epinephrine auto-injector

Most specialty pharmacies that dispense Egrifta SV offer a nurse training service. Request it explicitly when the prescription is filled.

Documentation the Caregiver Should Maintain at Home

Keep a simple injection log with:

• Date and time of each injection
• Injection site used (e.g., "right abdomen, upper quadrant")
• Lot number from the vial
• Any reactions noted and their duration

This log helps the physician identify patterns (e.g., worse reactions from a particular lot) and supports insurance documentation for off-label use.

Special Considerations: Contraindications and Drug Interactions

Absolute Contraindications

Tesamorelin must not be given to a child with:

• Active malignancy or a history of malignancy (GH stimulation may promote tumor growth) [1]
• Known hypersensitivity to tesamorelin or mannitol (an excipient in Egrifta SV)
• Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary surgery (the drug requires an intact pituitary to work)
• Pregnancy (not applicable in this age group but listed for completeness)

Drug Interactions Relevant in Pediatric Patients

Tesamorelin may induce or alter the activity of CYP450 enzymes by changing GH and IGF-1 levels. In children receiving anticonvulsants metabolized via CYP3A4 (such as carbamazepine or phenytoin), GH-pathway changes can shift drug plasma levels. The prescribing physician should review all concurrent medications before starting tesamorelin. [1]

Glucocorticoids can blunt the GH response to tesamorelin. A child on chronic steroid therapy for asthma or an autoimmune condition may show a reduced IGF-1 response, which the physician must factor into dose decisions and monitoring intervals. [9]

When to Hold the Dose and When to Restart

Caregivers often face uncertainty about whether to give a scheduled dose when the child is unwell. The following guidance reflects general principles for GH-axis peptides; always defer to the prescribing physician's specific written instructions.

Hold the dose and call the prescriber if the child has:

• A fever above 38.5°C (101.3°F) accompanied by vomiting or inability to eat
• Active diarrheal illness affecting fluid balance
• A new injury or surgical procedure within the past 48 hours
• A fasting glucose above 126 mg/dL confirmed on two consecutive home readings

Resume the dose as usual if the child has:

• A mild common cold without fever
• Minor skin abrasion unrelated to the injection site
• A single elevated glucose that normalized the next morning

Missing one dose does not require a make-up injection. Never double the dose the following day. The endocrine system has no clinical need for catch-up dosing for a single missed injection of a GH-releasing agent.

Communicating With the Healthcare Team

Caregivers of children on off-label injectable therapies often feel isolated. Building a clear communication plan with the prescribing team before starting therapy reduces both errors and caregiver anxiety.

Confirm with the clinic:

• Which phone number to call for non-urgent questions during business hours
• Which number to use for after-hours urgent concerns
• The expected callback time for non-urgent messages
• The schedule for routine lab draws (IGF-1, fasting glucose, bone age)
• The name and direct contact for the dispensing specialty pharmacy

The Pediatric Endocrine Society's position statement on off-label endocrine drug use in children emphasizes that "caregivers must receive written instructions for the specific drug, dose, and monitoring plan, and must have access to a clinician by phone within 24 hours of any adverse event." [10]